Price T Rowe Associates Inc Candel Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 19,638 shares of CADL stock, worth $107,812. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,638
Previous 12,275
59.98%
Holding current value
$107,812
Previous $70,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
83Shares Held
15.3MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$14.2 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.6 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$9.81 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$8.9 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$4.96 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $159M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...